000			04292nam a22004575i 4500
001			u374106
003			SIRSI
005			20160812084218.0
007			cr nn 008mamaa
008			100427s2010 gw | s |||| 0|eng d
020			_a9783642117923 _9978-3-642-11792-3
040			_cMX-MeUAM
050		4	_aR856-857
082	0	4	_a610.28 _223
100	1		_aFernandez, Ariel. _eauthor.
245	1	0	_aTransformative Concepts for Drug Design: Target Wrapping _h[recurso electrónico] / _cby Ariel Fernandez.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2010.
300			_aX, 224p. 80 illus., 40 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aProtein Cooperativity and Wrapping: Two Themes in the Transformative Platform of Molecular Targeted Therapy -- Wrapping Defects and the Architecture of Soluble Proteins -- Folding Cooperativity and the Wrapping of Intermediate States of Soluble Natural Proteins -- Wrapping Deficiencies and De-wetting Patterns in Soluble Proteins: A Blueprint for Drug Design -- Under-Wrapped Proteins in the Order–Disorder Twilight: Unraveling the Molecular Etiology of Aberrant Aggregation -- Evolution of Protein Wrapping and Implications for the Drug Designer -- Wrapping as a Selectivity Filter for Molecular Targeted Therapy: Preliminary Evidence -- Re-engineering an Anticancer Drug to Make It Safer: Modifying Imatinib to Curb Its Side Effects -- Wrapping Patterns as Universal Markers for Specificity in the Therapeutic Interference with Signaling Pathways -- Fulfilling a Therapeutic Imperative in Cancer Treatment: Control of Multi-target Drug Impact -- Inducing Folding By Crating the Target -- Wrapper Drugs as Therapeutic Editors of Side Effects -- Wrapper Drugs for Personalized Medicine -- Last Frontier and Back to the Drawing Board: Protein–Water Interfacial Tension in Drug Design.
520			_aIn spite of the enticing promises of the post-genomic era, the pharmaceutical world is in a state of disarray. Drug discovery seems now riskier and more uncertain than ever. Thus, projects get routinely terminated in mid-stage clinical trials, new targets are getting harder to find, and successful therapeutic agents are often recalled as unanticipated side effects are discovered. Exploiting the huge output of genomic studies to make safer drugs has proven to be much more difficult than anticipated. More than ever, the lead in the pharmaceutical industry depends on the ability to harness innovative research, and this type of innovation can only come from one source: fundamental knowledge. This book squarely addresses this crucial problem since it introduces fundamental discoveries in basic biomolecular research that hold potential to broaden the technological base of the pharmaceutical industry. The book takes a fresh and fundamental look at the problem of how to design an effective drug with controlled specificity. Since the novel transformative concepts are unfamiliar to most practitioners, the first part of this book explains matters very carefully starting from a fairly elementary physico-chemical level. The second part of the book is devoted to practical applications, aiming at nothing less than a paradigm shift in drug design. This book is addressed to scientists working at the cutting edge of research in the pharmaceutical industry, but the material is at the same time accessible to senior undergraduates or graduate students interested in drug discovery and molecular design.
650		0	_aEngineering.
650		0	_aOncology.
650		0	_aBiochemistry.
650		0	_aBiomedical engineering.
650	1	4	_aEngineering.
650	2	4	_aBiomedical Engineering.
650	2	4	_aMedicinal Chemistry.
650	2	4	_aBiophysics and Biological Physics.
650	2	4	_aCancer Research.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783642117916
856	4	0	_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-3-642-11792-3
596			_a19
942			_cLIBRO_ELEC
999			_c201986 _d201986